I am a board-certified therapeutic radiologic medical physicist at MSK Commack. I provide clinical physics services in all aspects of radiation therapy to ensure high-quality patient care.
I have a broad background in physics, mathematics, and computer programming. My main research interests are proton therapy treatment-planning methods, optimization techniques, and motion management. I have published many peer-reviewed articles and numerous abstracts. I frequently serve as a peer reviewer for many prestigious journals.
Upon receiving my PhD from the University of Massachusetts in 2011, I went on to a research fellowship at Massachusetts General Hospital. I later moved to the Hospital of the University of Pennsylvania for a one-year fellowship in medical physics and a clinical residency. I was certified by the American Board of Radiology in 2017 and became a faculty member at Memorial Sloan Kettering in February 2018.
I am a member of the American Association of Physicists in Medicine and the American Society for Radiation Oncology.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Chuan Zeng discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.